In tis issue:
Setrobuvir-based regimens in treatment-naïve GT1 HCV
2015 APASL guidelines for HBV management
Sofosbuvir+velpatasvir in treatment-experienced GT1/3 HCV
Predicting risk of HBeAg– hepatitis in later life
Sofosbuvir+ribavirin for chronic HEV in the immunocompromised?
Tenofovir+Peg-IFN α-2a promising in chronic HBV
Treat HCV/HIV co-infection regardless of stage?
NZ experiences of live liver donation
Blood-borne virus seroprevalence in UK EDs
Liraglutide promising in NASH
Please login below to download this issue (PDF)